A prediction model for response to immune checkpoint inhibition in advanced melanoma

Isabella A. J. van Duin,Rik J. Verheijden,Paul J. van Diest,Willeke A. M. Blokx,Mary‐Ann El‐Sharouni,Joost J. C. Verhoeff,Tim Leiner,Alfonsus J. M. van den Eertwegh,Jan Willem B. de Groot,Olivier J. van Not,Maureen J. B. Aarts,Franchette W. P. J. van den Berkmortel,Christian U. Blank,John B. A. G. Haanen,Geke A. P. Hospers,Djura Piersma,Rozemarijn S. van Rijn,Astrid A. M. van der Veldt,Gerard Vreugdenhil,Michel W. J. M. Wouters,Marion A. M. Stevense‐den Boer,Marye J. Boers‐Sonderen,Ellen Kapiteijn,Karijn P. M. Suijkerbuijk,Sjoerd G. Elias
DOI: https://doi.org/10.1002/ijc.34853
2024-02-02
International Journal of Cancer
Abstract:What's new? Only about half of patients with advanced melanoma respond to immune checkpoint inhibitor (ICI) therapy, but it is still difficult to predict which patients will benefit. Here, the authors present a prediction model for response to anti‐PD‐1‐based therapy in patients with advanced melanoma. They based the model on characteristics of the primary melanoma and clinical variables from the metastatic setting that are readily available from routine clinical care. The model predicts response to ICI in patients with advanced melanoma and distinguishes well between patients with a very good and very poor prognosis. Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients with advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical data including primary melanoma characteristics. We used a population‐based cohort of 3525 patients with advanced cutaneous melanoma treated with anti‐PD‐1‐based therapy. Our prediction model for predicting response within 6 months after ICI initiation was internally validated with bootstrap resampling. Performance evaluation included calibration, discrimination and internal–external cross‐validation. Included patients received anti‐PD‐1 monotherapy (n = 2366) or ipilimumab plus nivolumab (n = 1159) in any treatment line. The model included serum lactate dehydrogenase, World Health Organization performance score, type and line of ICI, disease stage and time to first distant recurrence—all at start of ICI—, and location and type of primary melanoma, the presence of satellites and/or in‐transit metastases at primary diagnosis and sex. The over‐optimism adjusted area under the receiver operating characteristic was 0.66 (95% CI: 0.64–0.66). The range of predicted response probabilities was 7%–81%. Based on these probabilities, patients were categorized into quartiles. Compared to the lowest response quartile, patients in the highest quartile had a significantly longer median progression‐free survival (20.0 vs 2.8 months; P
oncology
What problem does this paper attempt to address?